表紙
市場調查報告書

預填充式注射器填充/完工服務市場 (2020∼2030年)

Prefilled Syringe Fill / Finish Services Market, 2020-2030

出版商 ROOTS ANALYSIS 商品編碼 926044
出版日期 內容資訊 英文 267 Pages
商品交期: 最快1-2個工作天內
價格
預填充式注射器填充/完工服務市場 (2020∼2030年) Prefilled Syringe Fill / Finish Services Market, 2020-2030
出版日期: 2020年02月29日內容資訊: 英文 267 Pages
簡介

預填充式注射器(及其他主要的藥物容器)的無菌藥的填充,認為是醫藥品製造流程中最重要的階段之一。無菌條件下實施的適當的填充/完工操作,不僅維持藥理效果和品質,還必須確保最終用戶的安全。

本報告提供全球預填充式注射器填充/完工服務市場未來展望相關分析,產品、服務的概要和市場基本結構,市場規模 (生產能力、需求量、市場收益額)的趨勢預測,各地區的詳細趨勢,主要企業的簡介和最新趨勢,資本交易、事業聯盟的動向,未來的市場機會,產業相關人員的見解等資訊彙整,為您概述為以下內容。

第1章 簡介

第2章 摘要整理

第3章 簡介

  • 分析概要
  • 預填充式注射器的概要
    • 預填充式注射器的優點
    • 預填充式注射器的分類
    • 預填充式注射器的製造方法
  • 無菌注射劑的填充/完工工作的必要性
  • 為預填充式注射器填充/完工市場成長貢獻的要素
  • 預填充式注射器的填充/完工
    • 預填充式注射器的填充/完工工作:主要的次序
    • 填充、停止方法
    • 注射器填充技術
  • 為了選擇填充/完工服務業者的基本指南
  • 填充/完工服務的外包的優點
  • 填充/完工工作的外包的風險與課題

第4章 市場環境

  • 分析概要
  • 預填充式注射器填充/完工服務業者:整體市場形勢
    • 各成立年度分析
    • 各企業規模分析
    • 各產業規模分析
    • 各總公司所在地分分析
    • 填充/完工設備的各地點分析
    • 企業規模、各藥物分子類型分析
    • 注射器桶的各材質分析
    • 各注射器的填充產量分析
    • 各附加服務分析
    • 網格表現:各成立年度、各企業規模、各藥物分子類型分析
    • 標誌情勢:各企業規模、各藥物分子類型分析

第5章 北美的預填充式注射器填充/完工服務業者:企業簡介

  • 分析概要
  • Ajinomoto Bio-Pharma Services
    • 企業概要
    • 最近趨勢與未來展望
  • AMRI
  • BioPharma Solutions
  • Emergent BioSolutions
  • Patheon
  • PiSA Farmaceutica

第6章 歐洲的預填充式注射器填充/完工服務業者:企業簡介

  • 分析概要
  • Consort Medical
  • EVER Pharma
  • GlaxoSmithKline
  • IDT Biologika
  • Rentschler Biopharma
  • Siegfried
  • Vetter Pharma

第7章 亞太地區的預填充式注射器填充/完工服務業者:企業簡介

  • 分析概要
  • Biocon
  • Intas Pharmaceuticals
  • Kemwell Biopharma
  • Square Pharmaceuticals
  • USV

第8章 預填充式注射器填充/完工服務業者:最近的趨勢

  • 分析概要
  • 事業聯盟模式
  • 事業聯盟、合作的一覽
    • 事業聯盟:各締結年度分析
    • 事業聯盟:各種類的分析
    • 各產業規模分析(資本交易限制)
    • 各附加服務分析(資本交易限制)
    • 最活躍的企業:事業聯盟的締結數量分析
  • 事業擴張的一覽
    • 事業擴張:各實施年度分析
    • 事業擴張:各種類的分析
    • 事業擴張:各產業規模分析
    • 事業聯盟:擴張計劃的各地方分析
    • 事業聯盟:關係的各藥物分子類型分析
    • 各附加服務分析(事業擴張限制)

第9章 容量分析

  • 分析概要
  • 分析的前提條件與手法
  • 全球預填充式注射器的填充/完工設施:數量
    • 各企業規模分析(廠商)
    • 各產業規模分析
    • 各總公司所在地分析
    • 填充/完工設備的各地點分析
    • 各藥物分子類型分析
  • 全球預填充式注射器的填充/完工設施:容量
    • 各企業規模分析(廠商)
    • 各產業規模分析
    • 各總公司所在地分析
    • 填充/完工設備的各地點分析
    • 各藥物分子類型分析

第10章 需求分析

  • 分析概要
  • 分析的前提條件與手法
  • 預填充式注射器的填充/完工服務的世界需求
    • 各地區的分析
    • 各藥物分子類型分析
    • 治療領域的各分析
    • 注射器桶的各材質分析
    • 各桶室數分析
  • 需求與供給趨勢分析

第11章 需求與供給趨勢的各地區評估

  • 分析概要
  • 北美的供需趨勢的評估
  • 歐洲的供需趨勢的評估
  • 亞太地區、其他國家 (RoW)的供需趨勢的評估

第12章 有可能性的合作夥伴分析

  • 分析概要
  • 分析方法和主要指標
  • 可能性高的合作夥伴分析
    • 北美的機會
    • 歐洲的機會
    • 在亞太地區、其他國家 (RoW) 的機會

第13章 市場規模、機會分析

  • 分析概要
  • 預測手法主要的前提條件
  • 預填充式注射器填充/完工服務:市場規模 (全球,2020∼2030年)
    • 各經營規模 (2020∼2030年)
    • 各地點 (2020∼2030年)
    • 各藥物分子類型 (2020∼2030年)
    • 各治療領域 (2020∼2030年)
    • 各注射器桶材料 (2020∼2030年)
    • 各桶室數 (2020∼2030年)

第14章 成長機會

  • 分析概要
  • 擴大中的注射藥開發平台
  • 填充/完工工作的外包增加
  • 自體治療的上升趨勢
  • 預填充式注射器的人氣增加
  • 無菌填充/完工技術的進步

第15章 預填充式注射器廠商

  • 分析概要
  • 預填充式注射器:可利用的/開發中的設備的一覽
    • 各注射器桶材質
    • 各桶室數
    • 針系統的各類型
    • 各桶音量
  • 預填充式注射器:製造商清單
    • 各成立年度分析
    • 各企業規模分析
    • 各總公司所在地分析

第16章 結論

第17章 企業員工的見解:概要

  • 分析概要
  • Intas Pharmaceuticals
    • 公司概要
    • 受訪者的姓名、職位與回答內容 (概要)
  • IDT Biologika
  • IDEO
  • Syngene
  • 大CMO (受託製造廠商)

第18章 附錄1:資料表

第19章 附錄2:企業的一覽

目錄

Overview:

Among drug delivery devices, prefilled syringes represent one of the fastest growing primary packaging formats, which are also designed for dose administration. In fact, over the past ten years, there has been an evident increase in the development of parenteral drugs (especially with the introduction of several classes of biologics), which has resulted in an increased consumption of prefilled syringes, by approximately three fold. The sustained preference for such products can be attributed to the fact that prefilled syringes are safe and easy-to-use, and current variants are designed with provisions to reduce dosing errors, the risk of occlusions, extravasation and phlebitis. Owing to the aforementioned benefits, several injectable drugs (such as Humira®, Enbrel®, Avastin®, PREVNAR 13®, ALPROLIX® and Benefix®), diluents and other products requiring parenteral administration, are packaged in prefilled syringes. In fact, over the past seven years, around 90 drugs have been approved in combination with prefilled syringes across different geographies, including the North America, Europe and Asia-Pacific. Moreover, several clinical-stage drugs are being evaluated in combination with prefilled syringes, across different phases of development.

The filling of sterile drugs into prefilled syringes (and other primary drug containers) is considered to be one of the most crucial steps in the pharmaceutical production process. Proper fill / finish operations, carried out under aseptic conditions, is a necessity for not only maintaining pharmacological efficacy and quality, but also ensuring end user safety. The prefilled syringe filling operation is considered complex as it requires close monitoring of both the syringe fill volume as well as the headspace between the liquid in the syringe and the bottom of the plunger. Additionally, the rise in complexity of small molecule APIs and the increasing diversity of biologic drugs have also contributed towards the demand of advanced aseptic fill / finish operations. A number of small-sized companies and some large companies have outsourced their fill / finish operations to contract service providers. According to the 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, biomanufacturers have been shown to outsource over 30% of their fill / finish operations. With the increase in the demand for prefilled syringes, along with the growing complexity of fill / finish processes, the outsourcing of these operations is likely to increase further in the future. Currently, over 100 companies are actively providing fill / finish services for prefilled syringes. In order to cope up with the current and future market demand, service providers are actively investing in expanding their existing infrastructure and capabilities; companies are also expanding their client reach through service agreements in the past few years. Given that around 55% of drug candidates in the global R&D pipeline are injectables, the opportunities for prefilled syringe developers / manufacturers and affiliated service providers is anticipated to continue to grow over the next decade. In addition, owing to the recent COVID-19 pandemic, an increase in the development initiatives for the vaccines is likely to be witnessed in the near future. This is expected to significantly raise the demand for prefilled syringes, providing an additional impetus to the overall fill / finish services market.

The 'Prefilled Syringe Fill / Finish Service Providers, 2020-2030' report features an extensive study of the current market landscape and future opportunities for contract service providers offering fill finish services for prefilled syringes.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Introduction to Prefilled Syringes
    • 3.2.1. Advantages of Prefilled Syringes
      • 3.2.1.1. Benefits to Healthcare Professionals and End Users
      • 3.2.1.2. Benefits to Manufacturers
    • 3.2.2. Classification of Prefilled Syringes
    • 3.2.3. Manufacturing of Prefilled Syringes
  • 3.3. Need for Outsourcing Fill / Finish Operations of Sterile Injectables
  • 3.4. Factors Contributing to the Growth of Prefilled Syringe Fill / Finish Market
  • 3.5. Fill / Finish of Prefilled Syringes
    • 3.5.1. Key Steps in Fill / Finish Operations of Prefilled Syringes
    • 3.5.2. Filling and Stoppering Methods
    • 3.5.3. Syringe Filling Technologies
  • 3.6. Basic Guidelines for Selecting a Fill / Finish Service Provider
  • 3.7. Advantages of Outsourcing Fill / Finish Services
  • 3.8. Risks and Challenges of Outsourcing Fill / Finish Operations

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Prefilled Syringe Fill / Finish Service Providers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Scale of Operation
    • 4.2.4. Analysis by Location of Headquarters
    • 4.2.5. Analysis by Location of Fill / Finish Facilities
    • 4.2.6. Analysis by Company Size and Type of Drug Molecule
    • 4.2.7. Analysis by Syringe Barrel Material
    • 4.2.8. Analysis by Syringe Fill Volume
    • 4.2.9. Analysis by Additional Services Offered
    • 4.2.10. Grid Representation: Analysis by Year of Establishment, Company Size and Type of Drug Molecule
    • 4.2.11. Logo Landscape: Analysis by Company Size and Type of Drug Molecule
      • 4.2.5.1. World Map Representation: Analysis by Scale of operation and Location of Fill / Finish Facility

5. PREFILLED SYRINGE FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. Ajinomoto Bio-Pharma Services
    • 5.2.1. Company Overview
    • 5.2.2. Recent Developments and Future Outlook
  • 5.3. AMRI
    • 5.3.1. Company Overview
    • 5.3.2. Recent Developments and Future Outlook
  • 5.4. BioPharma Solutions
    • 5.4.1. Company Overview
    • 5.4.2. Recent Developments and Future Outlook
  • 5.5. Emergent BioSolutions
    • 5.5.1. Company Overview
    • 5.5.2. Recent Developments and Future Outlook
  • 5.6. Patheon
    • 5.6.1. Company Overview
    • 5.6.2. Recent Developments and Future Outlook
  • 5.7. PiSA Farmacéutica
    • 5.7.1. Company Overview
    • 5.7.2. Recent Developments and Future Outlook

6. PREFILLED SYRINGE FILL / FINISH SERVICE PROVIDERS IN EUROPE: COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Consort Medical
    • 6.2.1. Company Overview
    • 6.2.2. Recent Developments and Future Outlook
  • 6.3. EVER Pharma
    • 6.3.1. Company Overview
    • 6.3.2. Recent Developments and Future Outlook
  • 6.4. GlaxoSmithKline
    • 6.4.1. Company Overview
    • 6.4.2. Recent Developments and Future Outlook
  • 6.5. IDT Biologika
    • 6.5.1. Company Overview
    • 6.5.2. Recent Developments and Future Outlook
  • 6.6. Rentschler Biopharma
    • 6.6.1. Company Overview
    • 6.6.2. Recent Developments and Future Outlook
  • 6.7. Siegfried
    • 6.7.1. Company Overview
    • 6.7.2. Recent Developments and Future Outlook
  • 6.8. Vetter Pharma
    • 6.8.1. Company Overview
    • 6.8.2. Recent Developments and Future Outlook

7. PREFILLED SYRINGE FILL / FINISH SERVICE PROVIDERS IN ASIA-PACIFIC: COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. Biocon
    • 7.2.1. Company Overview
    • 7.2.2. Recent Developments and Future Outlook
  • 7.2. Intas Pharmaceuticals
    • 7.2.1. Company Overview
    • 7.2.2. Recent Developments and Future Outlook
  • 7.3. Kemwell Biopharma
    • 7.3.1. Company Overview
    • 7.3.2. Recent Developments and Future Outlook
  • 7.4. Square Pharmaceuticals
    • 7.4.1. Company Overview
    • 7.4.2. Recent Developments and Future Outlook
  • 7.5. USV
    • 7.5.1. Company Overview
    • 7.5.2. Recent Developments and Future Outlook

8. PREFILLED SYRINGE FILL / FINISH SERVICE PROVIDERS: RECENT DEVELOPMENTS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3 List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Scale of Operation (Deal Specific)
    • 8.3.5. Analysis by Additional Services Offered (Deal Specific)
    • 8.3.6. Most Active Players: Analysis by Number of Partnerships
  • 8.4. List of Expansions
    • 8.4.1. Analysis by Year of Expansion
    • 8.4.2. Analysis by Type of Expansion
    • 8.4.3. Analysis by Expanded Scale of Operation
    • 8.4.4. Analysis by Location of Expansion Project
    • 8.4.5. Analysis by Type of Drug Molecule Involved
    • 8.4.6. Analysis by Additional Services Offered (Expansion Specific)

9. CAPACITY ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Assumptions and Methodology
  • 9.3. Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units)
    • 9.3.1. Analysis by Company Size (Manufacturer)
    • 9.3.2. Analysis by Scale of Operation
    • 9.3.3. Analysis by Location of Headquarters
    • 9.3.4. Analysis by Location of Fill / Finish Facilities
    • 9.3.5. Analysis by Type of Drug Molecule
  • 9.4. Global, Prefilled Syringe Fill / Finish Capacity (by Volume)
    • 9.4.1. Analysis by Company Size (Manufacturer)
    • 9.4.2. Analysis by Scale of Operation
    • 9.4.3. Analysis by Location of Headquarters
    • 9.4.4. Analysis by Location of Fill / Finish Facilities
    • 9.4.5. Analysis by Type of Drug Molecule

10. DEMAND ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Assumptions and Methodology
  • 10.3. Global Demand for Prefilled Syringe Fill / Finish Services
    • 10.3.1. Analysis by Geography
    • 10.3.2. Analysis by Type of Drug Molecule
    • 10.3.3. Analysis by Therapeutic Area
    • 10.3.4. Analysis by Syringe Barrel Material
    • 10.3.5. Analysis by Number of Barrel Chambers
  • 10.4. Analysis of Demand and Supply Dynamics

11. GEOGRAPHICAL ASSESSMENT OF DEMAND AND SUPPLY

  • 11.1. Chapter Overview
  • 11.2. Demand and Supply Assessment in North America
  • 11.3. Demand and Supply Assessment in Europe
  • 11.4. Demand and Supply Assessment in Asia-Pacific and Rest of the World

12. LIKELY PARTNER ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Methodology and Key Parameters
  • 12.3. Likely Partner Analysis
    • 12.3.1. Opportunities in North America
      • 12.3.1.1. Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
      • 12.3.1.2. Likely Partners for Prefilled Syringe Fill / Finish Service Providers
    • 12.3.2. Opportunities in Europe
      • 12.3.2.1. Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
      • 12.3.2.2. Likely Partners for Prefilled Syringe Fill / Finish Service Providers
    • 12.3.3. Opportunities in Asia-Pacific and Rest of the World
      • 12.3.3.1. Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
      • 12.3.3.2. Likely Partners for Prefilled Syringe Fill / Finish Service Providers

13. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology and Key Assumptions
  • 13.3. Overall Prefilled Syringe Fill / Finish Services Market, 2020-2030
    • 13.3.1. Prefilled Syringe Fill / Finish Services Market: Distribution by Scale of Operation, 2020-2030
    • 13.3.2. Prefilled Syringe Fill / Finish Services Market: Distribution by Geographical Location, 2020-2030
    • 13.3.3. Prefilled Syringe Fill / Finish Services Market: Distribution by Type of Drug Molecule, 2020-2030
    • 13.3.4. Prefilled Syringe Fill / Finish Services Market: Distribution by Therapeutic Area, 2020-2030
    • 13.3.5. Prefilled Syringe Fill / Finish Services Market: Distribution by Syringe Barrel Material, 2020-2030
    • 13.3.6. Prefilled Syringe Fill / Finish Services Market: Distribution by Number of Barrel Chambers, 2020-2030

14. FUTURE GROWTH OPPORTUNITIES

  • 14.1. Chapter Overview
  • 14.2. Growing Injectable Drugs Pipeline
  • 14.3. Increase in Outsourcing of Fill / Finish Activities
  • 14.4. Rising Preference for Self-Medication
  • 14.5. Increase in Popularity of Prefilled Syringes
  • 14.6. Advances in Aseptic Fill / Finish Technologies

15. PREFILLED SYRINGE MANUFACTURERS

  • 15.1. Chapter Overview
  • 15.2. Prefilled Syringes: List of Available / Under Development Devices
    • 15.2.1. Analysis by Syringe Barrel Material
    • 15.2.2. Analysis by Number of Barrel Chambers
    • 15.2.3. Analysis by Type of Needle System
    • 15.2.4. Analysis by Barrel Volume
  • 15.3. Prefilled Syringes: List of Manufacturers
    • 15.3.1. Analysis by Year of Establishment
    • 15.3.2. Analysis by Company Size
    • 15.3.3. Analysis by Location of Headquarters

16. CONCLUDING REMARKS

  • 16.1. Chapter Overview
  • 16.2. Key Takeaways

17. INTERVIEW TRANSCRIPTS

  • 17.1. Chapter Overview
  • 17.2. Intas Pharmaceuticals
    • 17.2.1. Company Snapshot
    • 17.2.2. Interview Transcript: Kirti Maheshwari, Chief Technical Officer
  • 17.3. IDT Biologika
    • 17.3.1. Company Snapshot
    • 17.3.2. Interview Transcript: Gregor Kawaletz, Chief Commercial Officer
  • 17.4. IDEO
    • 17.4.1. Company Snapshot
    • 17.4.2. Interview Transcript: Jesse Fourt, Design Director
  • 17.5. Syngene
    • 17.5.1. Company Snapshot
    • 17.5.2. Interview Transcript: Purushottam Singnurkar, Research Director and Head of Formulation Development
  • 17.6. Large CMO
    • 17.6.1. Interview Transcript: Anonymous, Associate Director, Head of Process Sciences Formulation and Fill / Finish

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES

List Of Figures

  • Figure 3.1 Steps Involved in the Manufacturing of Prefilled Syringes
  • Figure 3.2 Steps Involved in Fill / Finish Operations of Prefilled Syringes
  • Figure 3.3 Key Considerations for Selecting a CMO Partner
  • Figure 3.4 Risks and Challenges Associated with Outsourcing Fill / Finish Operations
  • Figure 4.1 Prefilled Syringe Fill / Finish Service Providers: Distribution by Year of Establishment
  • Figure 4.2 Prefilled Syringe Fill / Finish Service Providers: Distribution by Company Size
  • Figure 4.3 Prefilled Syringe Fill / Finish Service Providers: Distribution by Scale of Operation
  • Figure 4.4 Prefilled Syringe Fill / Finish Service Providers: Distribution by Location of Headquarters
  • Figure 4.5 Prefilled Syringe Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
  • Figure 4.6 Prefilled Syringe Fill / Finish Service Providers: Distribution by Company Size and Type of Drug Molecule
  • Figure 4.7 Prefilled Syringe Fill / Finish Service Providers: Distribution by Syringe Barrel Material
  • Figure 4.8 Prefilled Syringe Fill / Finish Service Providers: Distribution by Syringe Fill Volume
  • Figure 4.9 Prefilled Syringe Fill / Finish Service Providers: Distribution by Additional Services Offered
  • Figure 4.10 Grid Representation: Distribution by Year of Establishment, Company Size and Type of Drug Molecule
  • Figure 4.11 Logo Landscape: Distribution by Company Size and Type of Drug Molecule
  • Figure 4.12 World Map Representation: Distribution by Scale of Operation and Location of Fill / Finish Facility
  • Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership, 2015-2019
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Distribution by Scale of Operation (Deal Specific)
  • Figure 8.4 Partnerships and Collaborations: Distribution by Additional Services Offered (Deal Specific)
  • Figure 8.5 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.6 Expansions: Distribution by Year of Expansion, 2015-2019
  • Figure 8.7 Expansions: Distribution by Type of Expansion
  • Figure 8.8 Expansions: Distribution by Expanded Scale of Operation
  • Figure 8.9 Expansions: Distribution by Location of Expansion Project
  • Figure 8.10 Expansions: Distribution by Type of Drug Molecule Involved
  • Figure 8.11 Expansions: Distribution by Additional Services Offered (Expansion Specific)
  • Figure 9.1 Global, Prefilled Syringe Fill / Finish Capacity: Distribution of Capacity by Size of Manufacturer (Sample Data Set)
  • Figure 9.2 Global, Prefilled Syringe Fill / Finish Capacity: Distribution by Company Size of Manufacturer (in Million Units)
  • Figure 9.3 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Scale of Operation (in Million Units)
  • Figure 9.4 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Location of Headquarters (in Million Units)
  • Figure 9.5 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Location of Fill / Finish Facilities (in Million Units)
  • Figure 9.6 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Type of Drug Molecule (in Million Units)
  • Figure 9.7 Global, Prefilled Syringe Fill / Finish Capacity: Distribution by Company Size of Manufacturer (in Million Liters)
  • Figure 9.8 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Scale of Operation (in Million Liters)
  • Figure 9.9 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Location of Headquarters (in Million Liters)
  • Figure 9.10 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Location of Fill / Finish Facilities (in Million Liters)
  • Figure 9.11 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Type of Drug Molecule (in Million Liters)
  • Figure 10.1 Global, Demand for Prefilled Syringe Fill / Finish Services
  • Figure 10.2 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Geography
  • Figure 10.3 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Type of Drug Molecule
  • Figure 10.4 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Therapeutic Area
  • Figure 10.5 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Syringe Barrel Material
  • Figure 10.6 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Number of Barrel Chambers
  • Figure 10.7 Global, Prefilled Syringe Fill / Finish Services: Demand and Supply Dynamics
  • Figure 11.1 Demand and Supply Assessment: North America
  • Figure 11.2 Demand and Supply Assessment: Europe
  • Figure 11.3 Demand and Supply Assessment: Asia-Pacific and Rest of the World
  • Figure 12.1 Likely Partner Analysis: Distribution by Geography
  • Figure 13.1. Overall Prefilled Syringe Fill / Finish Services Market, 2020-2030 (USD Billion)
  • Figure 13.2. Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Scale of Operation (USD Million)
  • Figure 13.3. Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Geographical Location (USD Million)
  • Figure 13.4. Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Type of Drug Molecule (USD Million)
  • Figure 13.5. Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 13.6. Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Syringe Barrel Material (USD Million)
  • Figure 13.7. Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Number of Barrel Chambers (USD Million)
  • Figure 14.1. Growth Opportunities for Prefilled Syringe Fill / Finish Service Providers
  • Figure 15.1 Prefilled Syringes: Distribution by Syringe Barrel Material
  • Figure 15.2 Prefilled Syringes: Distribution by Number of Barrel Chambers
  • Figure 15.3 Prefilled Syringes: Distribution by Type of Needle System
  • Figure 15.4 Prefilled Syringes: Distribution by Barrel Volume
  • Figure 15.5 Prefilled Syringe Manufacturers: Distribution by Year of Establishment
  • Figure 15.6 Prefilled Syringe Manufacturers: Distribution by Company Size
  • Figure 15.7 Prefilled Syringe Manufacturers: Distribution by Location of Headquarters

List Of Tables

  • Table 3.1 Classification of Prefilled Syringes
  • Table 4.1 Prefilled Syringe Fill / Finish Service Providers: List of Companies
  • Table 4.2 Prefilled Syringe Fill / Finish Service Providers: Information on Location of Fill / Finish Facilities
  • Table 4.3 Prefilled Syringe Fill / Finish Service Providers: Information on Type of Drug Molecule
  • Table 4.4 Prefilled Syringe Fill / Finish Service Providers: Information on Syringe Barrel Material
  • Table 4.5 Prefilled Syringe Fill / Finish Service Providers: Information on Syringe Fill Volume Range
  • Table 4.6 Prefilled Syringe Fill / Finish Service Providers: Information on Additional Services Offered
  • Table 4.6 Prefilled Syringe Fill / Finish Service Providers: Information on Fill / Finish Capability
  • Table 5.1 Ajinomoto Bio-Pharma Services: Company Snapshot
  • Table 5.2 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
  • Table 5.3 AMRI: Company Snapshot
  • Table 5.4 AMRI: Recent Developments and Future Outlook
  • Table 5.5 BioPharma Solutions: Company Snapshot
  • Table 5.6 BioPharma Solutions: Recent Developments and Future Outlook
  • Table 5.7 Emergent BioSolutions: Company Snapshot
  • Table 5.8 Emergent BioSolutions: Recent Developments and Future Outlook
  • Table 5.9 Patheon: Company Snapshot
  • Table 5.10 Patheon: Recent Developments and Future Outlook
  • Table 5.11 PiSA Farmacéutica: Company Snapshot
  • Table 5.12 PiSA Farmacéutica: Recent Developments and Future Outlook
  • Table 6.1 Consort Medical: Company Snapshot
  • Table 6.2 Consort Medical: Recent Developments and Future Outlook
  • Table 6.3 EVER Pharma: Company Snapshot
  • Table 6.4 EVER Pharma: Recent Developments and Future Outlook
  • Table 6.5 GlaxoSmithKline: Company Snapshot
  • Table 6.6 GlaxoSmithKline: Recent Developments and Future Outlook
  • Table 6.7 IDT Biologika: Company Snapshot
  • Table 6.8 IDT Biologika: Recent Developments and Future Outlook
  • Table 6.9 Rentschler Biopharma: Company Snapshot
  • Table 6.10 Rentschler Biopharma: Recent Developments and Future Outlook
  • Table 6.11 Siegfried: Company Snapshot
  • Table 6.12 Siegfried: Recent Developments and Future Outlook
  • Table 6.13 Vetter Pharma: Company Snapshot
  • Table 6.14 Vetter Pharma: Recent Developments and Future Outlook
  • Table 7.1 Biocon: Company Snapshot
  • Table 7.2 Biocon: Recent Developments and Future Outlook
  • Table 7.3 Intas Pharmaceuticals: Company Snapshot
  • Table 7.4 Intas Pharmaceuticals: Recent Developments and Future Outlook
  • Table 7.5 Kemwell Biopharma: Company Snapshot
  • Table 7.6 Kemwell Biopharma: Recent Developments and Future Outlook
  • Table 7.7 Square Pharmaceuticals: Company Snapshot
  • Table 7.8 Square Pharmaceuticals: Recent Developments and Future Outlook
  • Table 7.9 USV: Company Snapshot
  • Table 7.10 USV: Recent Developments and Future Outlook
  • Table 8.1 Prefilled Syringe Fill / Finish Service Providers: Partnerships and Collaborations, 2015-2019
  • Table 8.2 Prefilled Syringe Fill / Finish Service Providers: Recent Expansions, 2015-2019
  • Table 9.1 Global Prefilled Syringe Fill / Finish Capacity (by Number of Units): Average Capacity by Company Size of Manufacturer (Sample Data Set)
  • Table 12.1 Opportunities in North America: Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
  • Table 12.2 Opportunities in North America: Likely Partners for Prefilled Syringe Fill / Finish Service Providers
  • Table 12.3 Opportunities in Europe: Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
  • Table 12.4 Opportunities in Europe: Likely Partners for Prefilled Syringe Fill / Finish Service Providers
  • Table 12.5 Opportunities in Asia-Pacific and Rest of the World: Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
  • Table 12.6 Opportunities in Asia-Pacific and Rest of the World: Likely Partners for Prefilled Syringe Fill / Finish Service Providers
  • Table 15.1 Prefilled Syringes: List of Available / Under Development Devices
  • Table 16.1 Prefilled Syringe Fill / Finish Services Market: Key Takeaways
  • Table 17.1 Intas Pharmaceuticals: Key Highlights
  • Table 17.2 IDT Biologika: Key Highlights
  • Table 17.3 IDEO: Key Highlights
  • Table 17.4 Syngene: Key Highlights
  • Table 18.1 Prefilled Syringe Fill / Finish Service Providers: Distribution by Year of Establishment
  • Table 18.2 Prefilled Syringe Fill / Finish Service Providers: Distribution by Company Size
  • Table 18.3 Prefilled Syringe Fill / Finish Service Providers: Distribution by Scale of Operation
  • Table 18.4 Prefilled Syringe Fill / Finish Service Providers: Distribution by Location of Headquarters
  • Table 18.5 Prefilled Syringe Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
  • Table 18.6 Prefilled Syringe Fill / Finish Service Providers: Distribution by Company Size and Type of Drug Molecule
  • Table 18.7 Prefilled Syringe Fill / Finish Service Providers: Distribution by Syringe Barrel Material
  • Table 18.8 Prefilled Syringe Fill / Finish Service Providers: Distribution by Syringe Fill Volume
  • Table 18.9 Prefilled Syringe Fill / Finish Service Providers: Distribution by Additional Services Offered
  • Table 18.10 Partnerships and Collaborations: Distribution by Year of Partnership, 2015-2019
  • Table 18.11 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 18.12 Partnerships and Collaborations: Distribution by Scale of Operation (Deal Specific)
  • Table 18.13 Partnerships and Collaborations: Distribution by Additional Services Offered (Deal Specific)
  • Table 18.14 Most Active Players: Distribution by Number of Partnerships
  • Table 18.15 Expansions: Distribution by Year of Expansion, 2015-2019
  • Table 18.16 Expansions: Distribution by Type of Expansion
  • Table 18.17 Expansions: Distribution by Expanded Scale of Operation
  • Table 18.18 Expansions: Distribution by Location of Expansion Project
  • Table 18.19 Expansions: Distribution by Type of Drug Molecule Involved
  • Table 18.20 Expansions: Distribution by Additional Services Offered (Expansion Specific)
  • Table 18.21 Global, Prefilled Syringe Fill / Finish Capacity: Distribution of Capacity by Size of Manufacturer (Sample Data Set)
  • Table 18.22 Global, Prefilled Syringe Fill / Finish Capacity: Distribution by Company Size of Manufacturer (in Million Units)
  • Table 18.23 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Scale of Operation (in Million Units)
  • Table 18.24 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Location of Headquarters (in Million Units)
  • Table 18.25 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Location of Fill / Finish Facilities (in Million Units)
  • Table 18.26 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Type of Drug Molecule (in Million Units)
  • Table 18.27 Global, Prefilled Syringe Fill / Finish Capacity: Distribution by Company Size of Manufacturer (in Million Liters)
  • Table 18.28 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Scale of Operation (in Million Liters)
  • Table 18.29 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Location of Headquarters (in Million Liters)
  • Table 18.30 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Location of Fill / Finish Facilities (in Million Liters)
  • Table 18.31 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Type of Drug Molecule (in Million Liters)
  • Table 18.32 Global, Demand for Prefilled Syringe Fill / Finish Services
  • Table 18.33 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Geography
  • Table 18.34 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Type of Drug Molecule
  • Table 18.35 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Therapeutic Area
  • Table 18.36 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Syringe Barrel Material
  • Table 18.37 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Number of Barrel Chambers
  • Table 18.38 Demand and Supply Assessment: North America
  • Table 18.39 Demand and Supply Assessment: Europe
  • Table 18.40 Demand and Supply Assessment: Asia-Pacific and Rest of the World
  • Table 18.41 Likely Partner Analysis: Distribution by Geography
  • Table 18.42 Overall Prefilled Syringe Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 18.43 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios, (USD Million)
  • Table 18.44 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Geographical Location, Conservative, Base and Optimistic Scenarios, (USD Million)
  • Table 18.45 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Type of Drug Molecule, Conservative, Base and Optimistic Scenarios, (USD Million)
  • Table 18.46 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, (USD Million)
  • Table 18.47 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Syringe Barrel Material, Conservative, Base and Optimistic Scenarios, (USD Million)
  • Table 18.48 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Number of Barrel Chambers, Conservative, Base and Optimistic Scenarios, (USD Million)
  • Table 18.49 Prefilled Syringes: Distribution by Syringe Barrel Material
  • Table 18.50 Prefilled Syringes: Distribution by Number of Barrel Chambers
  • Table 18.51 Prefilled Syringes: Distribution by Type of Needle System
  • Table 18.52 Prefilled Syringes: Distribution by Barrel Volume
  • Table 18.53 Prefilled Syringe Manufacturers: Distribution by Year of Establishment
  • Table 18.54 Prefilled Syringe Manufacturers: Distribution by Company Size
  • Table 18.55 Prefilled Syringe Manufacturers: Distribution by Location of Headquarters

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. AbbVie Contract Manufacturing
  • 2. Aguettant
  • 3. AJ Biologics
  • 4. Ajinomoto Bio-Pharma Services
  • 5. Akron Biotech
  • 6. Akums Drugs and Pharmaceuticals
  • 7. Alanza
  • 8. Alcami
  • 9. Alfasigma
  • 10. Alkermes
  • 11. AMRI
  • 12. APL
  • 13. Aristopharma
  • 14. Austrianova
  • 15. Automated Systems of Tacoma
  • 16. Axcellerate Pharma
  • 17. Bahrain Pharma
  • 18. Baxter
  • 19. Becton Dickinson
  • 20. Berkshire Sterile Manufacturing
  • 21. Beximco Pharma
  • 22. Bio Elpida
  • 23. Biocon
  • 24. BioConnection
  • 25. Biomedical Advanced Research and Development Authority
  • 26. BioPharma Solutions
  • 27. Biotech Vision Care
  • 28. BirgiMefar
  • 29. Boehringer Ingelheim BioXcellence
  • 30. Bryllan
  • 31. CARBOGEN AMCIS
  • 32. Catalent Biologics
  • 33. Cenexi
  • 34. Cerium Pharmaceuticals
  • 35. CinnaGen
  • 36. Ciron Drugs and Pharmaceutical
  • 37. Cobra Biologics
  • 38. Consort Medical
  • 39. Cook Pharmica
  • 40. CordenPharma
  • 41. Dalton Pharma Services
  • 42. Delpharm
  • 43. Dhruv Life sciences
  • 44. DM Bio
  • 45. EirGen Pharma
  • 46. Emcure Pharmaceuticals
  • 47. Emergent BioSolutions
  • 48. Eurofins BioPharma
  • 49. European Medical Contract Manufacturing
  • 50. EVER Pharma
  • 51. ExCellThera
  • 52. FACET
  • 53. Fresenius Kabi Contract Manufacturing
  • 54. Gadea Pharmaceutical Group
  • 55. Genovior Biotech
  • 56. Gerresheimer
  • 57. Gland Pharma
  • 58. GP Pharm
  • 59. Grand River Aseptic Manufacturing
  • 60. GlaxoSmithKline
  • 61. Gulf Biotech
  • 62. Health Biotech
  • 63. Healthcare Pharmaceuticals
  • 64. Hetero Drugs
  • 65. Hisun Pharmaceuticals USA
  • 66. IDEO
  • 67. IDT Biologika
  • 68. Injectalia
  • 69. Intas Pharmaceuticals
  • 70. Integrity Bio
  • 71. Irisys
  • 72. Italfarmaco
  • 73. Kemwell Biopharma
  • 74. Kilitch Healthcare
  • 75. KP Pharmaceutical Technology
  • 76. Lifecore Biomedical
  • 77. LSNE Contract Manufacturing
  • 78. Lubrizol Life Science Health
  • 79. Medefil
  • 80. Mithra
  • 81. Mitsubishi Gas Chemical
  • 82. Mycenax Biotech
  • 83. Nipro
  • 84. Northway Biotechpharma
  • 85. Nova Laboratories
  • 86. Ology Bioservices
  • 87. OmniChem
  • 88. Ompi
  • 89. Oncotec Pharma Produktion
  • 90. Patheon
  • 91. PCI Pharma Services
  • 92. Pfizer CentreOne
  • 93. Pfizer Injectables
  • 94. Pharmaceutics International
  • 95. Pierre Fabre
  • 96. PiSA Farmacéutica
  • 97. Polpharma Biologics
  • 98. Praxis Pharmaceutical
  • 99. Precision Ocular Metrology
  • 100. PrimaPharma
  • 101. PYRAMID Laboratories
  • 102. Reliance Life Sciences
  • 103. Rentschler Biopharma
  • 104. Rompharm
  • 105. Rovi CM
  • 106. Samsung Bioepis
  • 107. Samsung Biologics
  • 108. Sandoz
  • 109. Saudi Biotech Manufacturing
  • 110. Schott
  • 111. Schott Kaisha
  • 112. ScinoPharm
  • 113. Selecta Biosciences
  • 114. Sewa Medicals
  • 115. Shandong Pharmaceutical Glass
  • 116. Shandong Weigao
  • 117. Sharp Corporation
  • 118. SHL Group
  • 119. Siegfried
  • 120. Singota Solutions
  • 121. Sovereign Pharma
  • 122. Square Pharmaceuticals
  • 123. Sunshine Health Products
  • 124. Swissfillon
  • 125. Symphogen
  • 126. Syngene
  • 127. Taisei Kako
  • 128. Taiyo Yakuhin
  • 129. Tanvex BioPharma
  • 130. Terumo
  • 131. Tolmar
  • 132. TriPharm Services
  • 133. Unicep
  • 134. United States Army Medical Materiel Development Activity
  • 135. USV
  • 136. Vanrx Pharmasystems
  • 137. VELIT Biopharmaceuticals
  • 138. Vetter Pharma
  • 139. VxP Biologics
  • 140. West Pharmaceuticals
  • 141. Wockhardt
  • 142. Zen Pharma